Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy

AUTOR(ES)

Bacon, Teresa H.

FONTE

American Society for Microbiology

RESUMO

Acyclovir, penciclovir, and their prodrugs have been widely used during the past two decades for the treatment of herpesvirus infections. In spite of the distribution of over 2.3 × 106 kg of these nucleoside analogues, the prevalence of acyclovir resistance in herpes simplex virus isolates from immunocompetent hosts has remained stable at approximately 0.3%. In immuncompromised patients, in whom the risk for developing resistance is much greater, the prevalence of resistant virus has also remained stable but at a higher level, typically 4 to 7%. These observations are examined in the light of characteristics of the virus, the drugs, and host factors.

Documentos Relacionados

• Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir
• Susceptibilities of Herpes Simplex Viruses to Penciclovir and Acyclovir in Eight Cell Lines
• Development of Clinical Resistance to Acyclovir in Herpes Simplex Virus-Infected Mice Receiving Oral Therapy
• Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapy.
• In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2.